Detalhe da pesquisa
1.
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.
Am J Gastroenterol
; 118(11): 2088-2092, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314163
2.
Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.
Gut
; 71(7): 1350-1358, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702716
3.
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Expert Opin Biol Ther
; 24(1-2): 101-109, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38250818
4.
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome.
Minerva Gastroenterol (Torino)
; 69(1): 123-127, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36856276
5.
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis.
United European Gastroenterol J
; 11(7): 642-653, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550901
6.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
; 29(3): 376-383, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579320
7.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Expert Opin Pharmacother
; 24(14): 1649-1656, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358928
8.
Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease.
Minerva Gastroenterol (Torino)
; 68(2): 216-222, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262307
9.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
; 31(4): 411-416, 2022 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535057
10.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
; 22(2): 313-320, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904510
11.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
J Gastrointestin Liver Dis
; 30(4): 456-461, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34812437
12.
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Eur J Gastroenterol Hepatol
; 33(5): 670-679, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741797
13.
Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
J Gastrointestin Liver Dis
; 28(suppl. 4): 45-48, 2019 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31930223
14.
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study.
United European Gastroenterol J
; 4(4): 604-13, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27536372